Modification of the tremorigenic activity of physostigmine.
Drugs which reduce central catecholamine activity increased the tremorigenic action physostigmine (0.25 mg/kg) in the rat. The potentiation of physostigmine tremor induced by these neuroleptic drugs was quantitated measuring the ratio of post- to prephysostigmine motor activity; this ratio may be useful index of catecholamine/cholinergic balance. Of the compounds tested, chlorpromazine HC1 (15 mg/kg) and reserpine (10 mg/kg) had the greatest potentiating effect on the tremor-producing action of physostigmine. LDOPA (500 mg/kg) reduced the tremor induced by physostigmine in rats pre-treated with reserpine, but not in rats pre-treated with chlorpromazine.
D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D002395:Catecholamines / Q000037:antagonists & inhibitors; D002746:Chlorpromazine / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D004295:Dihydroxyphenylalanine / Q000494:pharmacology; D004357:Drug Synergism; D009043:Motor Activity / Q000187:drug effects; D010830:Physostigmine / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D051381:Rats; D012110:Reserpine / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D013997:Time Factors; D014202:Tremor / Q000139:chemically induced*
D002395:Catecholamines; D004295:Dihydroxyphenylalanine; D012110:Reserpine; D010830:Physostigmine; D002746:Chlorpromazine